Rasitrio (aliskiren;amlodipine;hydrochlorothiazide)
- Region
- 🇪🇺 EU
- Active substance
- aliskiren;amlodipine;hydrochlorothiazide
- Company
- Novartis Europharm Ltd.
- Status
- Withdrawn
- Therapeutic area
- Hypertension
- EU approval
- Tue 22 Nov 2011
- Application
- EMEA/H/C/002017
- ATC
- C09XA54
- Official record
- www.ema.europa.eu
Indication
Rasitrio is indicated for the treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently at the same dose level as in the combination.
Regulatory milestones
No milestones recorded in the last year.
Follow Rasitrio
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.